Media headlines about Ultragenyx Pharmaceutical (NASDAQ:RARE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.9625938833536 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Ultragenyx Pharmaceutical (NASDAQ RARE) traded down $0.62 during mid-day trading on Thursday, hitting $46.97. 234,461 shares of the company traded hands, compared to its average volume of 438,366. Ultragenyx Pharmaceutical has a 52 week low of $43.14 and a 52 week high of $91.35. The company has a market cap of $2,060.00, a price-to-earnings ratio of -6.74 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.87). Ultragenyx Pharmaceutical had a negative net margin of 40,013.64% and a negative return on equity of 79.94%. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. During the same quarter last year, the firm earned ($1.64) EPS. The firm’s quarterly revenue was up 81.8% compared to the same quarter last year. analysts anticipate that Ultragenyx Pharmaceutical will post -7.27 EPS for the current year.

Several analysts have recently weighed in on the stock. Raymond James Financial restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Friday, December 15th. BidaskClub cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Canaccord Genuity set a $80.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, December 5th. Barclays raised their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 5th. Finally, Jefferies Group upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and raised their price objective for the company from $58.00 to $72.00 in a research report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $72.40.

COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Earns News Impact Rating of 0.20” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.